Abstract
Serum levels of β-amyloid (A) peptides may represent an early biomarker in the diagnosis of Alzheimer’s disease (AD). In the present study, we investigated the temporal kinetic changes in the levels of serum Aβ 1-42 and 40 in an amyloid precursor protein (APP)/presenilin (PS)1 double transgenic mouse model of AD. Serum Aβ peptide levels in 2-, 3-, 6-, 9- and 18-month old, and liver Aβ 1-40 level in 6-month old mice were measured using enzyme-linked immunosorbent assay (ELISA) kits. Results revealed that serum Aβ levels peaked in 3-month old transgenic mice, and the Aβ level in non-transgenic and transgenic mice is comparable in liver. Compared to the 6-month old transgenic mice, Congo red staining showed that the 3-month old transgenic mice had minimum brain Aβ plaques, corresponding to the early stage of Alzheimer-like plaque pathology, and confocal microscope images showed that the deposition of Aβ in their cerebral vessels was minimal. Furthermore, results of the water maze test, showed that memory was normal for the 3- month old transgenic mice when compared to age-matched non-transgenic mice. These results suggest that serum Aβ peptide levels may be peaked during the early stage of AD. Monitoring serum Aβ peptide levels in the potential AD population may provide an early diagnosis of AD prior to the appearance of clinical symptoms.
Keywords: APP/PS1 double transgenic mouse model, serum, -amyloid, Alzheimer’s disease, plaque, memory.
Current Alzheimer Research
Title:Serum β-Amyloid Peptide Levels Spike in the Early Stage of Alzheimer- Like Plaque Pathology in an APP/PS1 Double Transgenic Mouse Model
Volume: 10 Issue: 9
Author(s): Jue He, Jin-Ping Qiao, Shenghua Zhu, Mengzhou Xue, Wenwu Chen, Xinchun Wang, Adrien Tempier, Qingjun Huang, Jiming Kong and Xin-Min Li
Affiliation:
Keywords: APP/PS1 double transgenic mouse model, serum, -amyloid, Alzheimer’s disease, plaque, memory.
Abstract: Serum levels of β-amyloid (A) peptides may represent an early biomarker in the diagnosis of Alzheimer’s disease (AD). In the present study, we investigated the temporal kinetic changes in the levels of serum Aβ 1-42 and 40 in an amyloid precursor protein (APP)/presenilin (PS)1 double transgenic mouse model of AD. Serum Aβ peptide levels in 2-, 3-, 6-, 9- and 18-month old, and liver Aβ 1-40 level in 6-month old mice were measured using enzyme-linked immunosorbent assay (ELISA) kits. Results revealed that serum Aβ levels peaked in 3-month old transgenic mice, and the Aβ level in non-transgenic and transgenic mice is comparable in liver. Compared to the 6-month old transgenic mice, Congo red staining showed that the 3-month old transgenic mice had minimum brain Aβ plaques, corresponding to the early stage of Alzheimer-like plaque pathology, and confocal microscope images showed that the deposition of Aβ in their cerebral vessels was minimal. Furthermore, results of the water maze test, showed that memory was normal for the 3- month old transgenic mice when compared to age-matched non-transgenic mice. These results suggest that serum Aβ peptide levels may be peaked during the early stage of AD. Monitoring serum Aβ peptide levels in the potential AD population may provide an early diagnosis of AD prior to the appearance of clinical symptoms.
Export Options
About this article
Cite this article as:
He Jue, Qiao Jin-Ping, Zhu Shenghua, Xue Mengzhou, Chen Wenwu, Wang Xinchun, Tempier Adrien, Huang Qingjun, Kong Jiming and Li Xin-Min, Serum β-Amyloid Peptide Levels Spike in the Early Stage of Alzheimer- Like Plaque Pathology in an APP/PS1 Double Transgenic Mouse Model, Current Alzheimer Research 2013; 10 (9) . https://dx.doi.org/10.2174/15672050113106660159
DOI https://dx.doi.org/10.2174/15672050113106660159 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Carbazole Scaffold in Medicinal Chemistry and Natural Products: A Review from 2010-2015
Current Topics in Medicinal Chemistry The Cannabinergic System as a Target for Anti-inflammatory Therapies
Current Topics in Medicinal Chemistry Cigarette Smoking and Hypertension
Current Pharmaceutical Design Arylglyoxals as Versatile Synthons for Heterocycles Through Multi-Component Reactions
Current Organic Chemistry The Role of Amitriptyline in the Management of Non-small Cell Lung Cancer
Current Cancer Therapy Reviews Curcumin Nanomedicine: A Road to Cancer Therapeutics
Current Pharmaceutical Design Exploring the Role of “Brahmi” (Bacopa monnieri and Centella asiatica) in Brain Function and Therapy
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery A Transient Survival Model of Alteration of Electrophysiological Properties Due to Amyloid Beta Toxicity Based on SH-SY5Y Cell Line
Current Alzheimer Research Subject Index to Volume 11
Current Medicinal Chemistry Evaluation of Small Molecule Tuberculostats for Targeting Tuberculosis Infections of the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry FDG-PET in the Evaluation of Brain Metabolic Changes Induced by Cognitive Stimulation in aMCI Subjects
Current Radiopharmaceuticals Alterations of Brain Membranes in Schizophrenia: Impact of Phospholipase A2
Current Topics in Medicinal Chemistry Interaction of Buffalo Brain Cystatin with Serotonin
Current Nanoscience Current Opinion in the Pharmaceutical Management of Irritable and Inflammatory Bowel Diseases: Role of ATP
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery The Utility of Antiemetics in the Prevention and Treatment of Postoperative Nausea and Vomiting in Patients Scheduled for Laparoscopic Cholecystectomy
Current Pharmaceutical Design Outcome Prediction after Non-aneurysmal Non-traumatic Subarachnoid Hemorrhage
Current Neurovascular Research Pain and Obesity in the Older Adult
Current Pharmaceutical Design Alkaloids from Cyanobacteria with Diverse Powerful Bioactivities
Mini-Reviews in Medicinal Chemistry Applications and Limitations of Genetically Modified Mouse Models in Drug Discovery and Development
Current Drug Metabolism Repositioning of Drugs in Cardiometabolic Disorders: Importance and Current Scenario
Current Topics in Medicinal Chemistry